Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause
Janux Therapeutics' TRACTr platform shows promise with encouraging early data. Check out what leads me to maintain a “Strong ...
pharmaphorum1d
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
At the moment, Amgen looks like it has a sizeable lead in the DLL3 category, with other potential indications for tarlatamab, including neuroendocrine prostate cancer (in phase 1) and potentially ...
Morningstar15d
Cartography Announces Appointments of Four Industry and Academic Leaders to its Clinical Advisory Board
overseeing more than 30 oncology programs spanning IND filings through Phase 1/2, including the recently approved IMDELLTRA™ (TARLATAMAB-DLLE) a first-in-class DLL3-targeted bispecific T-cell ...
Business Wire15d
Cartography Announces Appointments of Four Industry and Academic Leaders to its Clinical Advisory Board
overseeing more than 30 oncology programs spanning IND filings through Phase 1/2, including the recently approved IMDELLTRA™ (TARLATAMAB-DLLE) a first-in-class DLL3-targeted bispecific T-cell engager ...
MedPage Today14d
Can Immunotherapy Go the Distance in ES/LS Small-Cell Lung Cancer?
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The point is, we often like things that go fast, including ...
Nasdaq16d
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
Late last month, Amgen announced the much-awaited 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy being ... Imdelltra (tarlatamab) was approved for pre-treated advanced ...
Zacks.com on MSN16d
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...